natgillin/translations-raw huggingface dataset:
Fremstillerens instruktion til den enkelte pen skal følges for isætning af cylinderampul, påsætning af nål og injektion.
The manufacturer’ s instructions with each individual pen must be followed for loading the cartridge, attaching the needle and administering the insulin injection.
Eli Lilly Nederland B. V., Grootslag 1- 5, 3991 RA Houten, Holland.
Eli Lilly Nederland B V., Grootslag 1-5, 3991 RA Houten, The Netherlands.
EU/ 1/ 97/ 007/ 004 5 x 3 ml Humalog cylinderampuller til brug i en 3 ml pen EU/ 1/ 97/ 007/ 023 2 x (5 x 3 ml) Humalog cylinderampuller til brug i en 3 ml pen
EU/ 1/ 96/ 007/ 004 EU/ 1/ 96/ 007/ 023
Humalog Mix25 100 E/ ml injektionsvæske, suspension i hætteglas
Humalog Mix25 100 U/ ml suspension for injection in vial
Humalog Mix25 er indiceret til behandling af patienter med diabetes mellitus, der kræver insulin til opretholdelse af normal glukose homøostase.
Humalog Mix25 is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
Virkningsvarigheden af insulin lispro protaminsuspension (BASAL) - delen af Humalog Mix25 svarer til virkningsvarigheden af basal insulin (isophan).
The duration of action of the insulin lispro protamine suspension (BASAL) component of Humalog Mix25 is similar to that of a basal insulin (NPH).
18 Hypoglykæmi.
18 Hypoglycaemia.
Insulinbehovet kan øges af lægemidler med hyperglykæmisk aktivitet, f. eks. orale antikonceptiva, kortikosteroider eller thyreoideahormon substitutionsterapi, danazol, beta2- stimulerende midler (såsom ritodrin, salbutamol, terbutalin).
Insulin requirements may be increased by substances with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f. eks. orale antidiabetika, salicylater (f. eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta- blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Lægen bør konsulteres, når der tages anden medicin samtidig med Humalog Mix25.
The physician should be consulted when using other medications in addition to Humalog Mix25.
19 Det er vigtigt at opretholde god kontrol med insulinbehandlede patienter (insulinkrævende eller svangerskabsbetinget diabetes) under graviditeten.
19 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
Lokale allergiske reaktioner er almindelig forekommende (≥1/ 100 til < 1/ 10).
Local allergy in patients is common (1/ 100 to < 1/ 10).
20 Vedvarende indtag af kulhydrater samt observation kan være nødvendigt, idet hypoglykæmi kan gentage sig efter en tilsyneladende klinisk bedring.
20 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
ATC kode:
ATC Code:
A10A D04.
A10A D04.
15 timer.
Humalog BASAL has an activity profile that is very similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
Kliniske forsøg med type 1 - og type 2- diabetikere har vist nedsat postprandial hyperglykæmi med Humalog Mix25 sammenlignet med human insulin blanding 30/ 70.
Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with Humalog Mix25 compared to human insulin mixture 30/ 70.
I et klinisk forsøg sås en svag (0, 38 mmol( l) stigning i blodglukoseniveauet om natten (klokken 3).
In one clinical study there was a small (0.38 mmol/ l) increase in blood glucose levels at night (3a. m.).
Humalog Mix25 Humalog Mix25 Humalog Basal NPL
Hypoglycemic Activity
Hypoglykæmisk aktivitet
Humalog Mix25 Humalog Basal
Det glukodynamiske respons på insulin lispro påvirkes ikke af nedsat nyre - eller leverfunktion.
21 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
21 Det er vist, at insulin lispro på molekylært niveau er lige så potent som human insulin, men dets effekt er hurtigere og af kortere varighed.
Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration.
Patienterne var enten nye i insulinbehandling eller brugte i forvejen en eller to insulininjektioner dagligt.
In two 8-month open label crossover studies, type 2 diabetes patients who were either new to insulin therapy or already using one or two injections of insulin, received 4 months of treatment with Humalog Mix25 (used twice daily with metformin) and insulin glargine (used once daily with metformin) in a randomised sequence.
Insulin- Naive Patienter n = 78
Insulin-Naive Patients n = 78
Ikke Insulin- Naive Patienter n = 97
Not Insulin-Naive Patients n = 97
Gennemsnitlig total daglig insulin dosis ved endpoint 1
Mean total daily insulin dose at endpoint 1
0, 63 E/ kg
0.63 U/ kg
0, 42 E/ kg
0.42 U/ kg
Hæmoglobin A1c – Reduktion
Haemoglobin A1c – Reduction
(gns. ved baseline = 8. 7%)
(mean at baseline = 8.7%)
(gns. ved baseline = 8. 5%)
(mean at baseline = 8.5%)
Reduktion af gennemsnittet morgen og aften to- timers postprandial blodglucose
Reduction of the mean of combined morning / evening two-hour postprandial 1 blood glucose
Reduktion af gennemsnitlig 1 blodglucose
Reduction of the mean fasting blood 1 glucose
FARMACEUTISKE OPLYSNINGER 22 6. 1 Fortegnelse over hjælpestoffer
PHARMACEUTICAL PARTICULARS
Saltsyre og natriumhydroxid kan være tilsat for at justere pH til 7, 0- 7, 8.
22 Protamine sulphate m-cresol [1.76 mg/ ml] Phenol [0.80 mg/ ml] Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.
Suspensionen skal anvendes indenfor 28 dage efter at hætteglasset er taget i brug.
After first use of the vial, the suspension should be used within 28 days, when stored below 30°C.
Suspensionen opbevares i Type 1 flintglas hætteglas, forseglede med butyl eller halobutyl gummimembraner og sikrede med aluminiumforseglinger.
The suspension is contained in type I flint glass vials, sealed with butyl or halobutyl stoppers and secured with aluminium seals.
23 2.
23 3.
Sug en mængde luft svarende til den ordinerede Humalog Mix25- dosis op i sprøjten.
Draw air into the syringe equal to the prescribed Humalog Mix25 dose.
Stik nålen igennem gummimembranen på Humalog Mix25- hætteglasset og sprøjt luften ind i glasset.
Put the needle through rubber top of the Humalog Mix25 vial and inject the air into the vial.
Vær sikker på, at spidsen af nålen befinder sig i Humalog Mix25- opløsningen og træk den korrekte dosis op i sprøjten.
Making sure the tip of the needle is in the Humalog Mix25, withdraw the correct dose into the syringe.
Før nålen fjernes fra hætteglasset, undersøges sprøjten for luftbobler, da disse nedsætter mængden af Humalog Mix25- opløsning.
Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog Mix25 in it.
Grootslag 1- 5, 3991 RA Houten, Holland.
Eli Lilly Nederland B. V., Grootslag 1-5, 3991 RA Houten, The Netherlands.
Humalog Mix25 100 E/ ml injektionsvæske, suspension i cylinderampul.
Humalog Mix25 100 U/ ml suspension for injection in cartridge
Virkningsvarigheden af insulin lispro protaminsuspension (BASAL) - delen af Humalog Mix25 svarer til virkningsvarigheden af basal insulin (isophan).
The duration of action of the insulin lispro protamine suspension (BASAL) component of Humalog Mix25 is similar to that of a basal insulin NPH.
25 Hypoglykæmi.
25 Hypoglycaemia.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f. eks. orale antidiabetika, salicylater (f. eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta- blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
26 Det er vigtigt at opretholde god kontrol med insulinbehandlede patienter (insulinkrævende eller svangerskabsbetinget diabetes) under graviditeten.
26 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
27 Vedvarende indtag af kulhydrater samt observation kan være nødvendigt, idet hypoglykæmi kan gentage sig efter en tilsyneladende klinisk bedring.
27 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Hypoglykæmisk aktivitet
Hypoglycaemic activity Humalog Mix25 Humalog Basal
De ovenfor anførte kurver illustrerer den relative mængde glukose, som over tid er nødvendig for at opretholde blodglukose- koncentrationer nær fasteniveau, og viser samtidig den tidsrelaterede effekt af disse insuliner på glukosemetabolismen.
The above representation reflects the relative amount of glucose over time required to maintain the subject's whole blood glucose concentrations near fasting levels and is an indicator of the effect of these insulins on glucose metabolism over time.
Det glukodynamiske respons på insulin lispro påvirkes ikke af nedsat nyre - eller leverfunktion.
28 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
28 Det er vist, at insulin lispro på molekylært niveau er lige så potent som human insulin, men dets effekt er hurtigere og af kortere varighed.
Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration.
1, 00%
1.30%
(gns.
1.00%
ved baseline = 8. 7%) 3, 46 mM
(mean at baseline = 8.7%)
(gns. ved baseline = 8. 5%) 2, 48 mM
(mean at baseline = 8.5%)
Reduktion af gennemsnitlig faste 1 blodglucose
Reduction of the mean of combined morning / evening two-hour postprandial 1 blood glucose
Hyppighed af hypoglykæmi ved endpoint
Reduction of the mean fasting blood 1 glucose
Stigning i legemesvægt2
Incidence of hypoglycaemia at endpoint Bodyweight gain2
FARMACEUTISKE OPLYSNINGER
29 6.1 List of excipients
Saltsyre og natriumhydroxid kan være tilsat for at justere pH til 7, 0- 7, 8.
Protamine sulphate m-cresol [1.76 mg/ ml] Phenol [0.80 mg/ ml] Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.
Suspensionen skal anvendes indenfor 28 dage efter at cylinderampullen er monteret i en pen.
After insertion of the cartridge in a pen, the suspension should be used in 28 days when stored below 30°C.
Suspensionen opbevares i Type 1 flintglas cylinderampuller, forseglede med butyl eller halobutyl gummimembraner og stempelhoveder og sikrede med aluminiumforseglinger.
The suspension is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and plunger heads and secured with aluminium seals.
Dimeticon eller silikone emulsion kan være brugt til behandling af stemplet og/ eller cylinderampullen.
Dimeticone or silicone emulsion may have been used to treat the cartridge plunger, and/ or the glass cartridge.
5 x 3 ml Humalog Mix25 cylinderampuller til brug i en 3 ml pen 2 x (5 x 3 ml) Humalog Mix25 cylinderampuller til brug i en 3 ml pen.
2 x (5 x 3 ml) Humalog Mix25 cartridges for a 3 ml pen.
Instruktioner vedrørende anvendelse og håndtering Humalog Mix25 cylinderampuller er beregnet til at blive brugt sammen med en CE mærket pen, som anbefalet i brugsanvisningen fra fremstilleren af pennen.
Instructions for use and handling Humalog Mix25 cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Insulinet skal fremtræde ensartet uklart eller mælkehvidt.
Cartridges containing Humalog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
30 Cylinderampullerne bør kontrolleres jævnligt og bør ikke bruges, hvis de indeholder klumper, eller hvis faste hvide partikler, der ligner rimfrost, har sat sig fast på bunden eller på siden af ampullen.
The cartridges should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.
Humalog Mix25 cylinderampuller er udformet således, at andet insulin ikke kan blandes i ampullen.
30 Humalog Mix25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Cylinderampullerne kan ikke genfyldes.
Cartridges are not designed to be refilled.
EU/ 1/ 96/ 007/ 008 5 x 3 ml Humalog Mix25 cylinderampuller til brug i en 3 ml pen EU/ 1/ 96/ 007/ 024 2 x (5 x 3 ml) Humalog Mix25 cylinderampuller til brug i en 3 ml pen
EU/ 1/ 96/ 007/ 008 EU/ 1/ 96/ 007/ 024
Humalog Mix50 100 E/ ml injektionsvæske, suspension i hætteglas
Humalog Mix50 100 U/ ml suspension for injection in vial
Humalog Mix50 beatår af 50% insulin lispro opløsning og 50% insulin lispro protaminsuspension.
Humalog Mix50 consists of 50% insulin lispro solution and 50% insulin lispro protamine suspension
Humalog Mix50 er indiceret til behandling af patienter med diabetes mellitus, der kræver insulin til opretholdelse af normal glukose homøostase.
Humalog Mix50 is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
Virkningsvarigheden af insulin lispro protaminsuspension (BASAL) - delen af Humalog Mix50 svarer til virkningsvarigheden af basal insulin (isophan).
The duration of action of the insulin lispro protamine suspension (BASAL) component of Humalog Mix50 is similar to that of a basal insulin (NPH).
32 Hypoglykæmi.
32 Hypoglycaemia.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f. eks. orale antidiabetika, salicylater (f. eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta- blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide, or alcohol.
Lægen bør konsulteres, når der tages anden medicin samtidig med Humalog Mix50.
The physician should be consulted when using other medications in addition to Humalog Mix50.
33 Det er vigtigt at opretholde god kontrol med insulinbehandlede patienter (insulinkrævende eller svangerskabsbetinget diabetes) under graviditeten.
33 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
Diabetikere, der ammer, kan have behov for regulering af insulindosis og/ eller diæt.
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet, or both.
34 Vedvarende indtag af kulhydrater samt observation kan være nødvendigt, idet hypoglykæmi kan gentage sig efter en tilsyneladende klinisk bedring.
34 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Virkningsprofilen af Humalog BASAL svarer til virkningsprofilen af basal insulin (isophan) over en tidsperiode på ca.
Humalog BASAL has an activity profile that is very similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
Basal
Humalog Mix50 Humalog Basal
Tid,
Time, hours
Det glukodynamiske respons på insulin lispro påvirkes ikke af nedsat nyre - eller leverfunktion.
35 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
35 5. 2 Farmakokinetiske egenskaber
5.2 Pharmacokinetic properties
Saltsyre og natriumhydroxid kan være tilsat for at justere pH til 7, 0- 7, 8.
Protamine sulphate m-cresol [2.20 mg/ ml] Phenol [1.00 mg/ ml] Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0-7.8.
6. 4 Særlige opbevaringsforhold
36 6.4 Special precautions for storage
36 6. 5 Emballage (art og indhold)
6.5 Nature and contents of container
Instruktioner vedrørende anvendelse og håndtering Hætteglasset skal bruges sammen med en hensigtsmæssig sprøjte (100 E skala).
Instructions for use and handling The vial is to be used in conjunction with an appropriate syringe (100 U markings).
Sug en mængde luft svarende til den ordinerede Humalog Mix50- dosis op i sprøjten.
Draw air into the syringe equal to the prescribed Humalog Mix50 dose.
Stik nålen igennem gummimembranen på Humalog Mix50- hætteglasset og sprøjt luften ind i glasset.
Put the needle through rubber top of the Humalog Mix50 vial and inject the air into the vial.
Vær sikker på, at spidsen af nålen befinder sig i Humalog Mix50- opløsningen og træk den korrekte dosis op i sprøjten.
Making sure the tip of the needle is in the Humalog Mix50, withdraw the correct dose into the syringe.
Før nålen fjernes fra hætteglasset, undersøges sprøjten for luftbobler, da disse nedsætter mængden af Humalog Mix50- opløsning.
Before removing the needle from the vial, check the syringe for air bubbles that reduce the amount of Humalog Mix50 in it.
37 4.
37 3.
Humalog Mix50 100 E/ ml injektionsvæske, suspension i cylinderampul.
Humalog Mix50 100 U/ ml suspension for injection in cartridge
39 Hypoglykæmi.
39 Hypoglycaemia.
Insulinbehovet kan være nedsat under samtidig behandling med lægemidler med hypoglykæmisk aktivitet, f. eks. orale antidiabetika, salicylater (f. eks. acetylsalicylsyre), sulfapræparater, visse antidepressiva (monoaminooxidasehæmmere), visse angiotensin konverteringsenzym (ACE) hæmmere (captopril, enalapril), angiotensin II- receptorblokkere, beta- blokkere, octreotid eller alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants, (monoamine oxidase inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
40 Det er vigtigt at opretholde god kontrol med insulinbehandlede patienter (insulinkrævende eller svangerskabsbetinget diabetes) under graviditeten.
40 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
41 Vedvarende indtag af kulhydrater samt observation kan være nødvendigt, idet hypoglykæmi kan gentage sig efter en tilsyneladende klinisk bedring.
41 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Humalog Mix50 Mix50 Humalog NPL Humalog Basal
Humalog Mix50 Humalog Basal
Det glukodynamiske respons på insulin lispro påvirkes ikke af nedsat nyre - eller leverfunktion.
42 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
42 Farmakokinetikken af insulin lispro afspejler hurtig absorption og opnåelse af maksimal plasmakoncentration 30 - 70 minutter efter subkutan injektion.
The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection.
Suspensionen skal anvendes indenfor 28 dage efter at cylinderampullen er monteret i en pen.
43 After insertion of the cartridge in a pen, the suspension should be used in 28 days when stored below 30°C.
43 6. 5 Emballage (art og indhold)
6.5 Nature and contents of container
Instruktioner vedrørende anvendelse og håndtering Humalog Mix50 cylinderampuller er beregnet til at blive brugt sammen med en CE mærket pen, som anbefalet i brugsanvisningen fra fremstilleren af pennen.
Instructions for use and handling Humalog Mix50 cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Insulinet skal fremtræde ensartet uklart eller mælkehvidt.
Cartridges containing Humalog Mix50 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
Humalog Mix50 cylinderampuller er udformet således, at andet insulin ikke kan blandes i ampullen.
Humalog Mix50 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
EU/ 1/ 96/ 007/ 006 5 x 3 ml Humalog Mix50 cylinderampuller til brug i en 3 ml pen EU/ 1/ 96/ 007/ 025 2 x (5 x 3 ml) Humalog Mix50 cylinderampuller til brug i en 3 ml pen
EU/ 1/ 96/ 007/ 006 EU/ 1/ 96/ 007/ 025
Humalog BASAL 100 E/ ml injektionsvæske, suspension i cylinderampul.
Humalog BASAL 100 U/ ml suspension for injection in cartridge
Humalog BASAL er indiceret til behandling af patienter med diabetes mellitus, der kræver insulin til opretholdelse af normal glukose homøostase.
Humalog BASAL is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
4. 4 Særlige advarsler og forsigtighedsregler vedrørende brugen
46 4.4 Special warnings and precautions for use
46 Humalog BASAL bør under ingen omstændigheder gives intravenøst.
Under no circumstances should Humalog BASAL be given intravenously.
Lægen bør konsulteres, når der tages anden medicin samtidig med Humalog BASAL.
The physician should be consulted when using other medications in addition to Humalog BASAL.
Insulinbehovet nedsættes sædvanligvis under første trimester og øges under andet og tredje trimester.
Insulin requirements usually fall during the first trimester and
47 Diabetikere, der ammer, kan have behov for regulering af insulindosis og/ eller diæt.
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.
Vedvarende indtag af kulhydrater samt observation kan være nødvendigt, idet hypoglykæmi kan gentage sig efter en tilsyneladende klinisk bedring.
48 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Middelhurtigt virkende human insulin- analog.
Intermediate acting human insulin analogue.
6 timer efter administrationen.
Humalog BASAL has a prolonged absorption profile, achieving a maximum insulin concentration approximately 6 hours after dosing.
Når den kliniske relevans af disse kinetiske forhold overvejes, er det mere relevant at se på glukoseomsætningskurverne.
When considering the clinical relevance of these kinetics, it is more appropriate to examine the glucose utilisation curves.
Protaminsulfat m- cresol (1, 76 mg/ ml) Phenol (0, 80 mg/ ml) Glycerol Dinatriumphosphatheptahydrat Zinkoxid
Protamine sulphate m-cresol [1.76 mg/ ml] Phenol [0.80 mg/ ml] 49 Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.